Wednesday, December 6, 2023
HomeWeekly RoundupImminent arrival of dolutegravir stocks in the Western Cape

Imminent arrival of dolutegravir stocks in the Western Cape

Western Cape Health is expecting to receive stock of a new antiretroviral (ARV) treatment called dolutegravir (DTG) by September, a drug that can be used in conjunction with other ARVs as a first and second-line treatment. A Cape Argus report says this is according to spokesperson, Mark van der Heever, who also said they would only begin implementation once sufficient stock is available.

DTG was recently approved by the World Health Organisation (WHO), after preliminary results of a 96-week trial, that was conducted by a Johannesburg-based research group from the University of the Witwatersrand.

The report says according to national training co-ordinator for the Treatment Action Campaign, Luckyboy Mkhondwane, the smaller dosages of DTG will make adherence easier and storage more manageable.

[link url=""]Cape Argus report (subscription needed)[/link]

Subscribe to our Newsletter

Receive Medical Brief's free weekly e-newsletter.

* indicates required